[The results of a multicenter open observational study of the efficacy and safety of the dietary supplement Neururidine N in patients with acute nonspecific lower back pain in daily outpatient practice (the NEURO-N study)].

OBJECTIVE

To study the efficacy and safety of the use of high (200 mg) doses of uridine monophosphate in combination with choline (dietary supplement, dietary supplement, Neururidine N) in the treatment of patients with nonspecific back pain.

MATERIAL AND

METHODS

An open observational study was conducted, which included 101 patients with acute PB; group 1 included 65 patients who received Neurouridine N (1 caps/day) meloxicam (7.5-15 mg/day) and meloxicam (7.5-15 mg/day), 2nd - 36 patients who received only meloxicam (7.5-15 mg/day). The observation period is 30 days. The condition of the patients was assessed on the basis of a visual analog scale (VAS), Roland-Morris questionnaires (ORM) and general clinical impression (CGI).

RESULTS

The positive effect of treatment on reducing the severity of pain was noted according to the results of the VAS assessment. In patients of group 1, an earlier improvement in functional status was noted (starting from day 7) according to ORM data (p<0.01), A more pronounced decrease in pain intensity allowed patients of group 1 to stop taking NSAIDs after 14 days (p<0.01). Patients of the 1st group were statistically significantly more satisfied with the results of treatment (CGI questionnaire), the doctors who observed them also regarded the improvement in their condition as more significant compared to the 2nd group.

CONCLUSION

The use of dietary supplement Neururidine N is an effective and safe method of coanalgesic therapy in patients with acute LBP.